Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Protein–protein interactions (PPIs) govern all biological processes. Some small molecules
modulate PPIs through induced protein proximity. In particular, molecular glue degraders …

Background High-dose chemotherapy plus autologous stem-cell transplantation has been
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …

Background Daratumumab showed promising efficacy alone and with lenalidomide and
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Summary This International Myeloma Working Group consensus updates the disease
definition of multiple myeloma to include validated biomarkers in addition to existing …

Background Multiple myeloma is characterised by monoclonal paraprotein production and
osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression …

Background Lenalidomide plus dexamethasone is a reference treatment for relapsed
multiple myeloma. The combination of the proteasome inhibitor carfilzomib with …

The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …